European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading

MT Newswires Live08-22

European equities traded in the US as American depositary receipts were relatively flat late Thursday morning, nudging 0.07% higher to 1,461.21 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by internet browser company Opera (OPRA) and biopharmaceutical company Grifols (GRFS), which climbed 16% and 11%, respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and biotech firm Evaxion Biotech (EVAX), which rose 4.2% and 1.9%, respectively.

The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company Cellectis (CLLS), which lost 3.7% and 2.3%, respectively. They were followed by biopharmaceutical company Genfit (GNFT) and petroleum refiner Equinor (EQNR), which were down 1.8% each.

From the UK and Ireland, the gainers were led by biopharmaceutical companies TC Biopharm (TCBP) and Akari Therapeutics (AKTX), which rose 4.4% and 1.7%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Autolus Therapeutics (AUTL), which were up 1.2% and 1%, respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company NuCana (NCNA), which dropped 5.8% and 4.7%, respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Verona Pharma (VRNA), which fell 4.2% and 1.8%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment